BTIG has singled out Guardant Health as its preferred holding in the health care sector, raising its price target on the company to $190 from $160 and reiterating a Buy rating after a major insurer announced coverage for Guardant’s colorectal cancer screening blood test.
UnitedHealthcare said it will provide commercial coverage for the Guardant Shield test beginning August 1, 2026, for asymptomatic adults aged 45 to 75. That decision arrived less than two years after Shield received U.S. Food and Drug Administration approval on July 29, 2024, a timeline BTIG described as materially faster than prior examples in the market.
BTIG contrasted Shield’s reimbursement trajectory with that of Exact Sciences’ Cologuard, noting that Cologuard took nearly three years after FDA approval to obtain UnitedHealthcare coverage. Guardant shares reacted positively to the UnitedHealthcare announcement, rising by more than 8 percent on the news and trading up 58 percent year to date.
In adjusting its valuation, BTIG applied a 14.4 times multiple to its 2028 revenue estimate of $2.2 billion, then discounted that figure back 2.5 years at a 10 percent discount rate and assumed roughly 131 million shares outstanding to arrive at the $190 price target. The firm also highlighted that the coverage bulletin did not restrict Shield to second-line use, indicating it may be reimbursed on par with Cologuard as a first-line screening option.
BTIG suggested that the May 27, 2026 update to American Cancer Society guidelines could have influenced UnitedHealthcare’s decision, though the firm stopped short of asserting a direct causal relationship. BTIG also said it expects additional commercial insurers to follow UnitedHealthcare’s lead in the coming quarters, potentially expanding Shield’s market access.
Market analysts outside BTIG responded to the coverage announcement with their own price-target revisions. Bank of America raised its target on Guardant to $190, while Bernstein increased its target to $200.
Summary takeaways
- BTIG named Guardant Health its top health care pick and raised the firm's price target to $190 from $160, maintaining a Buy rating.
- UnitedHealthcare will cover the Guardant Shield blood test for asymptomatic individuals aged 45 to 75 starting August 1, 2026, less than two years after FDA approval on July 29, 2024.
- BTIG's valuation uses a 14.4x multiple on a 2028 revenue estimate of $2.2 billion, discounted 2.5 years at 10 percent, and assumes about 131 million shares outstanding.
Market and sector impact
- Biotech and diagnostics companies could see precedent if other insurers follow UnitedHealthcare’s decision.
- Health insurers and screening providers will be central to how coverage decisions translate into patient access and market share for screening tests.
Risks and uncertainties
- It is uncertain whether other commercial insurers will adopt coverage for Shield at the same pace as UnitedHealthcare; reimbursement roll-out remains a key variable for revenue realization.
- BTIG's price target depends on forward revenue estimates, a chosen valuation multiple and a discount rate; deviations from those assumptions would change the implied valuation.
- The role of updated medical society guidelines in the coverage decision is suggested but not definitive, leaving open questions about the durability and scope of reimbursement.
Analysts and investors will watch subsequent insurer decisions and uptake closely to determine how quickly Shield converts coverage into screening volumes and revenue. For now, the UnitedHealthcare decision represents a meaningful reimbursement milestone that accelerated Guardant’s path to broad commercial coverage compared with past precedent.